Abstract
JAMA. 2026 Nov 16. doi: 10.1001/jama.2026.25143. Online ahead of print.
ABSTRACT
IMPORTANCE: Blood biomarkers that reflect neurofibrillary tau burden, a defining hallmark of Alzheimer disease (AD), remain limited. Endogenously cleaved microtubule-binding region tau 243 (eMTBR-tau243) has shown promise when measured by mass spectrometry; a scalable immunoassay could broaden research access and support clinical evaluation.
OBJECTIVE: To determine whether plasma levels of eMTBR-tau measured by a novel immunoassay are associated with tau neurofibrillary tangle pathology defined by neuropathology and tau positron emission tomography (PET).
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included brain donors with antemortem plasma from 2 US autopsy cohorts, and individuals with plasma samples and tau PET from 2 imaging cohorts in Canada and Sweden, with visits between 2002 and 2025 depending on the cohort.
EXPOSURES: Plasma eMTBR-tau measured with an immunoassay and eMTBR-tau243 measured with mass spectrometry.
MAIN OUTCOMES AND MEASURES: Plasma eMTBR-tau levels across neuropathologic Braak neurofibrillary tangle stages (I-VI, ranging from tangles confined to the entorhinal region to widespread neocortical tangles) and tau-PET Braak stages (0-VI), expressed as fold changes. Correlations with regional tau-PET standardized uptake value ratios (SUVRs; higher values indicating more tau tangles), discrimination of regional tau-PET positivity (area under the curve [AUC]), and correlation with mass spectrometry-based eMTBR-tau243.
RESULTS: The study included 728 participants in 4 cohorts (median age by cohort, 71.0-83.5 years; 41.3%-56.6% female). In the 2 autopsy cohorts (n = 241 and n = 240), eMTBR-tau age- and sex-adjusted geometric means were 0.0021 pg/mL and 0.0040 pg/mL, respectively, at Braak stages I-II vs 0.107 pg/mL and 0.101 pg/mL at Braak stage VI (50.5-fold [95% CI, 26.3-97.0] and 25.2-fold [95% CI, 15.8-40.3] higher for stage VI vs stages I-II; P < .001 for both cohorts). In one imaging cohort (n = 99), compared with tau-PET Braak stage 0, eMTBR-tau levels were 11.0-fold (95% CI, 6.9-17.5) higher at stages III-IV and 59.9-fold (95% CI, 39.5-90.7) higher at stages V-VI. Among participants positive for amyloid-β (Aβ) in another imaging cohort (n = 50), the Spearman rank correlations for eMTBR-tau with tau-PET SUVRs were ρ = 0.52 (95% CI, 0.28-0.70) in Braak regions I-II, 0.76 (95% CI, 0.61-0.86) in regions III-IV, and 0.85 (95% CI, 0.75-0.91) in regions V-VI (all P < .001). Immunoassay and mass spectrometry measurements were strongly correlated (Spearman rank correlation, ρ = 0.93 in all participants [n = 108] and ρ = 0.96 in Aβ-positive participants [n = 54]) and discriminated tau-PET positivity similarly (n = 102; AUC range, 0.96-0.99 for the immunoassay and 0.97-0.99 for mass spectrometry).
CONCLUSIONS AND RELEVANCE: A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.
PMID:43038566 | DOI:10.1001/jama.2026.25143
UK DRI Authors